AbolerIS Pharma Announces €27 Million in Series A Financing led by Caixa Capital Risc to Advance its Novel Treatment Paradigm for Autoimmune and Inflammatory Diseases

by Caixa Capital Risc

AbolerIS Pharma, a Belgian biopharmaceutical company developing an entirely novel approach to the treatment of chronic autoimmune and inflammatory diseases, today announced a €27.3 million Series A ...

Read more
Subscribe to Directory
Write an Article

Highlight

Axon moves into Cloud Technology

by Axon Partners Group

cloud technology axon

Hercesa and Buenavista are developing 'C...

by Buenavista Equity Partners

The project addresses the high demand for quality accommodation around...

Photos Stream